Soligenix Inc ( (SNGX) ) has released its Q2 earnings. Here is a breakdown of the information Soligenix Inc presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases, with active segments in Specialized BioTherapeutics and Public Health Solutions. The latest earnings report for the quarter ending June 30, 2025, highlights a challenging financial period for Soligenix, with a reported net loss of $2.7 million for the three months and $5.65 million for the six months. The company did not generate any revenue during this period, as it primarily relies on government grants and contracts. Key financial metrics indicate a decrease in cash and cash equivalents from $7.8 million at the end of 2024 to $5.1 million by June 2025, alongside a significant increase in operating expenses, particularly in research and development, which rose to $3.6 million for the six months. Soligenix continues to focus on its strategic initiatives, including the development of HyBryte™ for cutaneous T-cell lymphoma and other pipeline programs, while actively seeking additional funding and strategic partnerships to support its operations. Looking ahead, the company faces liquidity challenges but remains committed to advancing its product candidates and exploring various financing options to sustain its operations through the first quarter of 2026.